# ABio-X

ABio-X is an Asset Manager based in Cambridge, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Founded:** 2021
- **Assets under management:** Undisclosed
- **Website:** www.abio-x.com
- **LinkedIn:** https://www.linkedin.com/company/abio-x

## Regulatory record

- **Reports private funds:** No

## About

A Biotech Holding Company Focused on Transformative Medicines and Breakthrough Technologies | ABIO-X incubates companies at the convergence of groundbreaking technologies and innovative science bringing transformative medicines and solutions to the global market. Each company will have its own product portfolio and operations managed by a separate leadership team and supported by a centralized shared services environment.

## Sectors

- Biotech & Pharmaceuticals
- Digital Health

## Offices

- Shanghai
- London
- Waltham
- Beijing

## People

- Sean Fu — CEO

## Questions

### Who runs investment decisions at ABio-X?

CEO Sean Fu leads the platform and its investment activities. Fu previously co-founded mRNA company RVAC Medicines and held leadership roles at Merck & Co. for 15 years. The broader leadership team brings operational experience from Sanofi, Johnson & Johnson, Simcere Pharmaceutical, and Everest Medicines.

### How does ABio-X source its portfolio companies?

ABio-X primarily originates assets internally by identifying novel pathways and targets, then building new companies around that science. The firm also makes direct investments into existing companies. Its team operates from hubs in Boston, Shanghai, London, and Beijing to access academic and industry innovation globally.

### Is ABio-X a venture capital fund or an operating company?

ABio-X is an incubation platform that creates and funds new life sciences companies. Each member company operates with its own leadership team and product portfolio, making the platform a hybrid between an asset manager and a decentralized biotech operating group.

### What is ABio-X's relationship with CBC Group?

CBC Group, Asia's largest healthcare-dedicated investment firm, provided the initial $300 million commitment that launched ABio-X in 2021. ABio-X operates as an independent platform backed by CBC Group's capital and healthcare-network reach.

### Which therapeutic areas does ABio-X avoid?

ABio-X does not publish a formal exclusion list. Its stated focus is on large and historically daunting diseases, targeting indications that matter through novel approaches. The firm has been active in oncology (via NiKang Therapeutics) and infectious disease/vaccines (via RVAC Medicines).

### Does ABio-X co-invest alongside other institutional investors?

ABio-X has not publicly disclosed a co-investment program. As an incubation platform funded by a single committed capital source, its primary model is wholly-owned creation of new companies, though direct investments and future partner participation remain possible as member companies advance.

## Related profiles

- [Nord Anglia Education](https://altss.com/profile/nord-anglia-education-limited)
- [Carica Sustainable Investments](https://altss.com/profile/carica-sustainable-investments)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/abio-x

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology